Clinical Course and Treatment of Ligneous Conjunctivitis in Children With Plasminogen Deficiency
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Congenital plasminogen deficiency causes impaired wound healing and growth of
pseudomembranous lesions over multiple parts of the body. The most common lesions involve
eyes and are known as Ligneous conjunctivitis. These can cause scarring of the sclera, vision
loss and even blindness. These pseudomembranous lesions are recur after surgical excisions,
administration of intra-ocular cyclosporine, autologous serum drops or corticosteroids.
Clinical data shows that these growths do not worsen and do not recur after administration of
plasminogen (either as concentrate or as plasma) in the eyes, locally or intravenously.
As plasminogen is not available as concentrate, we are using aliquoted allogenic plasma
provided by Canadian Blood Services for intra-ocular application. These will be applied to
eyes multiple times a day for a period of 6 weeks to 6 months depending on disease severity
and patient response. These may be used again if ligneous conjunctivitis recurs.
The patient will be followed for a period of 2 years at least. All serious adverse events
will be reported to Canadian Blood Services and Health Canada as appropriate.